Nicholas Collette joins HiberCell with 20 years of scientific research experience in of analytical chemistry, drug discovery and immunology. He brings drug development experience from multiple successful pharmaceutical companies, each of which resulted in commercial licensing of drug products that improve patients’ lives. Most recently, Nicholas developed methods and strategies to evaluate the effects of cancer drug therapy candidates on immune cells at Pfizer, leading to the selection of multiple drug candidates for clinical trial consideration.
Nicholas obtained an M.S. in comparative biomedical sciences with an immunology concentration from the College of Veterinary Medicine at North Carolina State University. His thesis project evaluated the properties of chemically synthesized molecules modeled after Echinacea purpurea alkylamides on immune cells.